ENDE Biofrontera About us ABOUT BIOFRONTERA Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with about 150 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi® for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. WE ARE DEEP IN DERMATOLOGY CONTACT Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen +49-214-87632-0 info@biofrontera.com Germany SERVICE Imprint Disclaimer Data Privacy Policy Terms and Conditions (German only) Purchasing conditions (German only) ABOUT BIOFRONTERA We have specialized in dermatology as your skin's health is our concern. We aim to protect and heal your skin with our innovative photodynamic therapy medication. BIOFRONTERA AG © 2021 all rights reserved This site uses third-party website tracking technologies to provide and continually improve our services, and to display advertisements according to users' interests. I agree and may revoke or change my consent at any time with effect for the future. DENY ACCEPT MORE Powered by